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Abstract 
We recently identified a differentiation inhibitory factor (I-factor) in mouse myeloid leukemia M1 cells as a murine homolog of the 
human nm23-H2 gene product, nm23 genes encode proteins that participate in tumor metastasis regulation and in various fundamental 
cellular processes, although their mechanisms of action are still unknown. Although all nm23 proteins contain nucleoside diphosphate 
(NDP) kinase activity, it has not been established that the enzyme activity mediated the various functions of nm23 proteins. In the present 
experiment, we examined the effect of nm23 proteins on various differentiation induction systems of human leukemic cells including 
HL-60, U937, HEL/S, KU812F, K562, and HEL cells. Native human erythrocyte NDP kinase protein inhibited the induction of erythroid 
differentiation of HEL, KU812 and K562 cells, but not the induction of monocytic or granulocytic differentiation of HL-60, U937 and 
HEL/S cells. The erythroid ifferentiation of HEL cells was inhibited by recombinant human m23-Hl, -H2, mouse nm23-M1, and -M2 
proteins. Moreover, both the mutant nm23-H2 his protein and truncated nm23-H2 protein containing N-terminal (1-60) peptide, which do 
not have NDP kinase activity, also inhibited erythroid ifferentiation of HEL cells. These results suggest hat (1) the differentiation 
inhibitory activity of I-factor/nm23 protein is not restricted to monocytic differentiation of M1 cells, (2) the inhibitory activity is 
exhibited without species specificity, and (3) the differentiation i hibitory activity of the nm23/NDP kinase protein is independent of its 
enzyme activity and requires the presence of N-terminal peptides. 
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1. In t roduct ion  
Mouse myeloid leukemia M1 cells, established from a 
spontaneous myeloid leukemia in an SL mouse, can be 
induced to differentiate along the monocyte/macrophage 
pathway by various inducers including dexamethasone, 
I c~,25-dihydroxyvitamin D~, interleukin 6, and leukemia 
inhibitory factor/D-factor [l,2]. The process of differentia- 
tion induced in M1 cells is similar to that of normal 
myeloid progenitor cells. 
We isolated differentiation-resistant M1 cell clones that 
could not be induced to differentiate into mature cells from 
the parent M 1 cells [3-5]. Activity to inhibit differentiation 
of M 1 cells (I-factor activity) was detected in a cell lysate 
and conditioned medium of the differentiation-resistant M 1 
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cells, but not in those of the parental cells [3-5]. Recently, 
we purified one of the I-factors from conditioned medium 
of differentiation-resistant M1 cells. The purified I-factor 
had a relative molecular mass of approximately 16 000- 
17 000 Da, and its amino acid sequence determined from 
cyanogen bromide fragments was identical with that of 
nm23/NDP kinase (EC 2.7.4.6) protein, which is involved 
in tumor metastasis [6,7]. These results suggested that the 
nm23/NDP kinase protein might be the I-factor that sup- 
presses differentiation of leukemic cells. 
nm23 was first identified as a gene expressed in lower 
amounts in highly metastatic rodent tumors than in poorly 
metastatic tumor cells [8]. Homologs of nm23 have been 
identified in development of Drosophila s awd [9] and of 
Dictyostelium as gip 17 [10]. The deduced amino acid 
sequences of the products of these nm23 genes were found 
to share high homology with NDP kinases in a variety of 
species. The nm23 proteins, as well as their evolutionary 
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homologs, have been demonstrated to have NDP kinase 
activity, although it has not been established that the 
enzyme activity mediates the biological effect of nm23 
[11-13]. In humans, NDP kinase A and B are identical to 
two isotypes of human nm23 homologs, named nm23-Hl 
and -H2, respectively [12,14]. Two isotypes of nm23 
homologs nm23-M1 and -M2, have also been found in 
mice [15]. Recently, another type of NDP kinase (NDPK- 
/3) in addition to NDPK-~, was identified in rats [16]. It 
is, therefore, very likely that mammalian nm23/NDP 
kinases have two isotypes with high mutual homology. 
Our previous results on amino acid sequence analysis 
showed that the purified I-factor is probably nm23-M2 
[6,7,15]. 
In the present work, we examined (1) whether the 
I-factor/nm23/NDP kinase proteins affect differentiation 
of human leukemic cells as well as M1 cells, and (2) 
whether the enzyme activity of the protein is essential for 
its differentiation i hibitory activity. 
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Fig. 1. SDS-PAGE analysis of purified wild-type nm23-H2 and mutant 
nm23-H2 Hi~ and nm23-H2-AX-CX protein. (A) SDS-PAGE gel was 
stained with Coomassie Blue dye, destained and photographed. (B) NDP 
kinase activity of nm23-H2 proteins detected by the phosphoenzyme 
intermediate by autoradiography. Lane 1, 0.2 >g of GST; lane 2, 0.2 /,g 
of nm23-H2 protein; lane 3, 0.2 #g of nm23-H2 Hi~ protein: lane 4, 0.2 
/~g of nm23-H2-AX-CX protein. 
2. Materials and methods 
2.1. Reagents 2.4. nm23 / NDP kinase proteins 
Highly purified transforming rowth factor-/31 (TGF- 
/31) was purchased from R and D Systems (Minneapolis, 
MN). l c~,25-Dihydroxyvitamin D 3 (VD 3) was obtained 
from Chugai Pharmaceutical (Tokyo, Japan). Hemin, all 
trans retinoic acid (RA), and 1-/3-D-arabinofuranosyl cyto- 
sine (Ara-C) were obtained from Sigma Chemicals (St. 
Louis, MO). 12-O-Tetradecanoylphorbol- 13-acetate (TPA) 
was obtained from Consolidated Midland (Brewster, NY). 
2.2. Cells and cell culture 
Human leukemia cell lines were cultured in suspension 
in RPMI-1640 medium supplemented with 10% fetal 
bovine serum and gentamicin sulfate at 37 ° C in a humidi- 
fied atmosphere of 5% CO 2 in air. The human leukemia 
cell lines used in the present experiment were as follows: 
monocytoid (U937 and HEL/S), myeloid (HL-60) and 
erythroid (K562, HEL, and KU812F) leukemia cells 
[17,1g]. 
2.3. Assay of cell growth and differentiation 
Cell numbers were counted in a Model ZM Coulter 
Counter (Coulter Electrics, Luton, UK). Reduction of ni- 
tro-blue tetrazolium (NBT) dye, measured as a 
myelomonocytic differentiation marker of HL-60, U937 
and HEL/S cells, was assayed as reported previously 
[17-20]. Erythroid differentiation of the cells was scored 
by benzidine staining as reported previously [21]. 
Hemoglobin contents were measured photometrically with 
benzidine, as reported by Testa et al. [22]. 
NDP kinase protein from human erythrocytes was ob- 
tained from Sigma. Its NDP kinase activity was 125 
units/mg protein, one unit of NDP kinase being defined as 
that converting 1.0 /xmol each of TDP and ATP to TTP 
and ADP per min at pH 7.6 in a coupled system with 
pyruvate kinase/lactate dehydrogenase. Murine and hu- 
man recombinant m23 proteins (nm23-Ml, -M2, -H 1, and 
-H2) were produced as fusion proteins with 26k Da glu- 
tathione S-transferase (GST) in Escherichia coli ( E. coli) 
and purified to homogeneity on SDS-PAGE as described 
previously [15,23]. Using site-directed mutagenesis of 
cDNA encoding nm23-H2, we created a mutant nm23- 
H2 Hi~ protein, in which His I1~ was replaced by Cys [24]. 
The mutant nm23-H2 Hi~ protein was produced as a fusion 
protein with GST in E. coli and purified to homogeneity 
on SDS-PAGE (Fig. 1) by the procedure described previ- 
ously [15,23]. To create a truncated nm23-H2 protein, we 
constructed plasmids expressing the N-terminal peptide 
1-60 (nm23-H2-AX-CX). The primers used for PCR of the 
5'end[ 1-180]region were as follows: sense primer, H2-AX, 
5'-GGGGATCCATGGCCAACCTGGAGCG-3' (primer 
contained a BamHI site); antisense primer, H2-CX, 5'-GG- 
GAATTCAGAATGGTCGGTCTTTCA-3' (primer con- 
tained a EcoRI site). This truncated protein was produced 
as a fusion protein with GST in E. coli and purified to 
homogeneity on SDS-PAGE (Fig. l) by the procedure 
described previously [15,23]. All the recombinant nm23 
GST fusion proteins were dialyzed against phosphate- 
buffered saline. We examined NDP kinase activity in 
nm23-H2, -H2 ai~, and -H2-AX-CX proteins by assay of 
phosphoenzyme formation described previously [15]. Nei- 
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ther nm23-H2 Hi~ nor nm23-H2-AX-CX protein contained 
NDP kinase activity (Fig. 1) 
3. Results  
3.1. Effects of nm23 / NDP kinase proteins on differentia- 
tion of various leukemic line cells 
We have reported thal the purified I-factor inhibited 
retinoic acid-induced monocytic differentiation of mouse 
myeloid leukemia WEHI-3BD + cells, in addition to M1 
cells [4]. In the present study, we examined the effects of 
nm23/NDP kinase proteins on various differentiation i - 
duction systems of human leukemic line cells. The ability 
of nm23/NDP kinase proteins to inhibit the induction by 
various inducers was measured. Human erythrocyte NDP 
kinase protein inhibited the erythroid ifferentiation (about 
50% inhibition) of HEL, K562 and KU812F (Figs. 2,3) 
cells, but did not inhibit other differentiation induction 
systems (less than 20% inhibition, Fig. 1). The NDP kinase 
protein did not inhibit Ara-C-induced erythroid ifferentia- 
tion of K562 cells (Fig. 2C). The inhibitory effect of NDP 
kinase protein on erythroid differentiation of HEL cells 
was clearly observed, therefore we used the HEL cells to 
examine the effect of various recombinant nm23 proteins. 
Since we detected some contaminants present in erythro- 
cyte NDP kinase preparation purchased from Sigma, we 
next examined the effect o:f purified and dialyzed recombi- 
nant nm23 proteins. Recombinant nm23-Hl and -H2 pro- 
teins also inhibited the erythroid differentiation of HEL 
cells by TGF-/31 (Fig. 4). At their effective concentrations, 
nm23/NDP kinase proteins had no effect on proliferation 
of HEL cells (data not shown). The differentiation in- 
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Fig. 2. Effects of NDP kinase protein on myelomonocytic (A,B) and 
erythroid (C,D) differentiation induction systems of human leukemia 
cells. HL-60 (A), U937 (B), K562 (C) and KU812F (D) cells were 
incubated with (O ,• )  or (O)  without differentiation inducers and the 
concentrations of NDP kinase protein indicated. NBT reducing activity 
(A,B) and benzidine positive cells (C,D) were determined as markers of 
myelomonocytic and erythroid differentiation, respectively. Values are 
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Fig. 3. Effect of NDP kinase protein on erythroid ifferentiation of HEL cells. HEL cells (5 ' 104/ml)  were incubated (0 )  with or (O)  without TGF-~ 1 (1 
ng/ml ,  A), hemin (5.  10 -s  M, B), RA (4.  10 -6 M, C) and the indicated concentrations of human erythrocyte NDP kinase protein. Cells were stained 
with benzidine for hemoglobin determination on day 4. Values are means 4- S.D. for 2 -4  separate xperiments. 
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concentrations of 0.01-10 ng/ml and the maximal effect 
was also observed at this range. At higher concentrations 
(more than 10 ng/ml) the inhibitory effect often decreased 
rather than increased. There were no marked ifferences in
the differentiation i hibitory activities of the isoforms of 
nm23/NDP kinase proteins (Fig. 4), although in some 
experiments nm23-H2 had higher inhibitory activity than 
nm23-H1 (data not shown), nm23-H1 and -H2 were fusion 
proteins with glutathione S-transferase (GST), but GST 
alone did not show any differentiation i hibitory activity 
(Fig. 4). Purified recombinant mouse nm23-M1 and -M2 
proteins also inhibited the TGF-fl-induced erythroid iffer- 
entiation of HEL cells (Fig. 4B). Erythroid differentiation 
induced by hemin, another differentiation i ducer of HEL 
cells, was also inhibited by nm23-H1 and -H2 (data not 
shown). The inhibition of erythroid differentiation by 
nm23-H2 was confirmed by determination of the 
hemoglobin content. The hemoglobin contents of TGF- 
/31-treated HEL cells and TGF-fll + nm23-H2 (0.1 
ng/ml)-treated HEL cells were 256 + 13 /zg 
hemoglobin/mg protein and 137 + 8 /xg hemoglobin/mg 
protein, respectively. These results indicate that, like cy- 
tokines, these nm23/NDP kinase proteins can inhibit the 
induction of erythroid ifferentiation of HEL cells when 
they are added to the culture medium, and that they show 
no species pecificity. 
3.2, Effects of mutant nm23 / H2 i4i,~ and truncated nm23- 
H2-AX-CX proteins on erythroid differentiation of HEL 
cells 
To determine the correlation of differentiation in- 
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Fig. 4. Effect of recombinant m23 proteins on TGF-/31-induced ery- 
throid differentiation of HEL cells. HEL cells (5. 104/ml) were incu- 
bated with TGF-/31 (0.5 ng/ml) and the indicated concentrations of
human nm23-Hl (A,O); human nm23-H2 (A,O); GST; (A,•) ,  mouse 
nm23-M1 (B,O); mouse nm23-M2 protein (B,O). Cells were stained 
with benzidine for hemoglobin determination on day 4. Values are 
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Fig. 5. Effect of the mutant nm23-H2 Hi~ and nm23-H2-AX-CX protein 
on TGF-/31-induced erythroid differentiaion of HEL cells. HEL cells 
(5- 104/ml) were incubated with the indicated concentrations of nm23-H2 
(A,O); the mutant nm23-H2 HB (A,O); GST (A,B, • ); nm23-H2-AX-CX 
(B, • )  in the presence of 0.5 ng/ml of TGF-/31. Cells were stained with 
benzidine for hemoglobin determination on day 4. Values are means + S.D. 
for 3 separate xperiments. 
teins, we examined the differentiation i hibitory activities 
of two mutant nm23-H2 proteins lacking NDP kinase 
activity (Fig. 1). One was the mutant nm23-H2 ni'~, which 
has Cys ~18 instead of His 118. This mutant cannot form a 
phosphoenzyme by ATP because His 1~8, which is the 
substrate for phosphoenzyme formation by ATP, is re- 
placed by a Cys residue [12,23]. The other mutant was 
truncated nm23-H2 protein (H2-AX-CX) which is the 
N-terminal (1-60) peptide of the nm23-H2 protein. Al- 
though these mutant nm23-H2 proteins lost completely 
their NDP kinase activity (Fig. 1), they inhibited signifi- 
cantly TGF-/3-induced erythroid differentiation of HEL 
cells at the concentration of 0.1-1 ng/ml (Fig. 5). These 
results indicate that the NDP kinase activity of the nm23-H2 
protein is not required for inhibition of erythroid ifferenti- 
ation. 
4. Discussion 
We examined the effects of nm23 proteins on various 
differentiation i duction systems of human leukemic ells 
in addition to mouse M1 cells, nm23 proteins did not 
affect the monocytic differentiation of human leukemic 
HL-60, U937 (Fig. 2) and HEL/S cells (data not shown), 
although they inhibited those of mouse leukemic (M 1 and 
WEHI3B-D ÷) cells [4]. However, the nm23 proteins inhib- 
ited the erythroid ifferentiation of human leukemic HEL, 
KU812F and K562 cells (Figs. 2,3). The erythroid iffer- 
entiation of HEL cells was very sensitive to the differentia- 
tion inhibitory action of nm23 proteins (Fig. 4). It is 
unknown how the proteins inhibit the erythroid ifferentia- 
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tion of human leukemic cells. It will be interesting to 
examine whether the same target of nm23 proteins is 
involved in the mechanisms of differentiation of both HEL 
cells and M1 cells. 
nm23 genes are implicated in tumor metastasis control 
through as yet unknown mechanisms. Depending on the 
cell type, metastatic spreztd has been correlated with both 
reduced nm23 expression [25-29], and with overexpres- 
sion of nm23 [30-34]. rim23 genes are also involved in 
controlling normal cellular functions, including cell prolif- 
eration [35], differentiation [6,36] motility [37,38], and 
development, as indicated by high degrees of homology 
between m23 genes and the Drosophi la  awd gene vital to 
normal fruit fly development [9]. All nm23/awd proteins 
show NDP kinase enzyme', activity [10-13], catalyzing the 
synthesis of non-adenine-containing nucleoside triphos- 
phates from nucleoside diphosphates. Moreover, 
nm23/NDP kinase proteiJls have been reported to interact 
with GTP-binding proteins [10,39], bind chromoglycate 
dye [40], autophosphorylate serine residues [41-43], and 
bind to DNA and stimulate transcription [44]. Of these 
functions of nm23 proteins, the gene regulatory function 
(PuF) has recently been shown to be independent of NDP 
kinase activity [45]. In the present study, we examined the 
correlation between the IXrDp kinase activity and the ery- 
throid differentiation i hibiting activity of nm23 proteins. 
Our results showed that the inhibitory activity is not solely 
mediated by its kinase activity and that a short N-terminal 
region of nm23 protein is required to inhibit erythroid 
differentiation of HEL cells (Fig. 5). 
We are now trying to determine the active domain of 
the nm23 protein required for its differentiation i hibitory 
activity. All previously identified nm23/NDP kinases, 
except that in bacteria, share the tripeptide, Arg-Glyl°6- 
Asp, which is the RGD consensus equence for the recog- 
nition of integrin family members [46]. Recently, the pres- 
ence of nm23 protein on the cell surface of some cell lines 
has been reported [47], although the molecular mechanism 
of the surface expression of nm23 protein is unknown. An 
intriguing possibility is that nm23 functions as a ligand for 
adhesive molecules of the integrin family. However, trun- 
cated nm23-H2 proteins lacking the C-terminal peptide 
containing the RGD consensus equence exhibited in- 
hibitory activity (Fig. 5). [n a preliminary experiment, we 
found that the mutant nm23-H2 RGD protein, which has 
Ser 1°6 instead of Gly J06, inhibited erythroid ifferentiation 
of HEL cells by TGF-/31, like the wild-type nm23-H2 
protein (unpublished ata). These results suggest hat the 
differentiation i hibiting ',activity is not mediated by the 
RGD consensus sequence of nm23 protein. The N-terminal 
peptide of the nm23-H2 protein, containing a leucine 
zipper motif, a serine phosphorylation site (Ser44), and a 
mutation site (Leu 48) reported in aggressive childhood 
neuroblastomas, was required to inhibit differentiation of 
HEL cells (Fig. 5). The mechanism by which the nm23 
protein inhibits induction of erythroid differentiation of 
HEL cells is unknown. It will be interesting to examine the 
presence of nm23 specific binding sites on HEL cells. 
Leone et al. reported that transfection of murine nm23-1 
cDNA into the highly metastatic K-1735 TK cell line 
resulted in altered responsiveness to TGF-/3 in vitro, in 
addition to a reduced incidence of primary tumor forma- 
tion and significant reduction in the metastatic potential in 
vivo [48]. TGF-/3 is an inducer of erythroid ifferentiation 
of HEL cells [18,49]. It is unknown whether exogenously 
added nm23 protein also attenuates the responsiveness of 
HEL cells to TGF-/3. rim23 protein inhibited not only 
TGF-/3-induced differentiation but also hemin-, and RA-in- 
duced differentiation of HEL cells (Fig. 3). Thus nm23 
protein may affect a common pathway of erythroid iffer- 
entiation by various inducers. 
On the basis of their nuclear localizations and potential 
leucine zipper motifs, nm23-H2 and nm23-Hl were pro- 
posed to function as transcription factors [14,25]. Postel et 
al. presented evidence that nm23-H2 is a transcription 
factor (PuF) and that one of its targets is the c-myc gene 
[44]. Recently, they reported that the NDP kinase activity 
of the nm23-H2/PuF protein is not required for its func- 
tion as a transcription factor [45]. It will be interesting to 
investigate whether the c-myc transcription factor activity 
of the nm23-H2 protein is required for its differentiation 
inhibiting activity. Although no clear correlation has yet 
been established between overexpression of c-myc and 
tumor metastasis, the converse relation between c-myc 
expression and cell differentiation is well documented [50]. 
For example, overexpression of transfected c-myc can 
block terminal differentiation of murine erythroleukemia 
cells. In human erythroleukemia cells, the role of c-myc 
expression is unclear. There is a report hat heroin-induced 
differentiation of HEL cells results in early increase c-myc 
expression [51], although various other results have been 
reported [52,53]. Studies are required on the role of nm23 
and c-myc in erythroid ifferentiation of human leukemic 
cells. 
In conclusion, the present data provide evidence that 
nm23 functions as a erythroid differentiation i hibitory 
factor in human leukemic cells independent of its NDP 
kinase activity and that a short N-terminal region of nm23 
protein is required to inhibit erythroid differentiation of 
HEL cells. 
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